FL H0227

Creates s. 456.0302, F.S., known as the "Stephanie Balais Act," establishing regulatory requirements for health care providers (licensed under chapters 458, 459, or 464) administering intravenous vitamin treatment outside of hospital settings.

Requires providers to obtain a completed self-screening risk assessment questionnaire from patients before treatment, provide information on side effects and risks, supply a visit summary, and notify the patient's designated physician of the treatment.

Mandates that each treatment location maintain a written emergency care plan including the nearest hospital's name and address, reasons for emergency transfer, and medical services to be used in an emergency.

Directs the Board of Nursing, Board of Medicine, and Board of Osteopathic Medicine to adopt rules on education/training requirements, self-screening assessments, patient disclosure, documentation, physician notification, and evaluation of administration practices.

Violations constitute grounds for disciplinary action; the requirements do not apply to intravenous vitamin treatments provided in facilities licensed under chapter 395 (hospitals). Effective July 1, 2024.